Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

This phase I/II tests the safety, side effects and best dose of ruxolitinib in combination with enzalutamide and how well it works in treating patients with prostate cancer that remains despite blocking hormone production (castration-resistant) and that has spread from where it first started to other places in the body (metastatic). Ruxolitinib, a kinase inhibitor, slows down the growth of the tumor by blocking the proteins, JAK1 and JAK2, tumors use to grow. Enzalutamide, an androgen receptor inhibitor, works by blocking the effects of androgen (a male reproductive hormone). This may help sto

Trial Details

NCT ID
NCT06616155
Phase
PHASE1 / PHASE2
Sponsor
University of Michigan Rogel Cancer Center
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Biopsy
  • Biospecimen Collection
  • Bone Scan
  • Computed Tomography
  • Enzalutamide
  • Ruxolitinib
Locations (sample)
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Ann Arbor, Michigan, United States|42.27756,-83.74088
  • Detroit, Michigan, United States|42.33143,-83.04575

Key Eligibility Criteria

  • Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information p…
  • Males age ≥ 18 years with progressive metastatic, castration-resistant prostate cancer, previous adenocarcinoma histology confirmation required
  • Ability to understand a written informed consent document, as determined by the study physician or designee
  • Surgical castration or continuous medical castration ≥ 8 weeks prior to screening; serum testosterone \< 50 ng/dL

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →